Following the takeover of the Temmler Group last December, Aenova has appointed Temmler’s ex-CEO Werner Schneider.
Schneider will serve on the top level of Aenova’s management team, with responsibility for business development, as Aenova attempt to successfully integrate its new acquisition and retain its talent.
Schneider has been CEO of Temmler since 2006 and before this role he served at Lichtwer Pharma as a member of the board responsible for research and development, together with production and technology.
Also as part of the Temmler assimilation, Aenova has appointed Matthias Utrata as Director of Tax, Treasury and Compliance, reporting directly to the CFO.
Utrata was previously responsible for finance, IT, HR and corporate communications at Temmler.
Speaking of the two, Aenova CEO Heiner Hoppmann said: “Their many years of experience of the pharmaceutical industry and their competence in this area will enable both of them to make a significant contribution to strengthening the position of the Aenova Group”
The Clondalkin Group has appointed David Lennon as Global CEO of its Pharmaceutical and Health Division.
Lennon has been Clondalkin’s European Chief since 2009 and he will now spearhead the roll-out of Clondalkin’s ambitious global business development plans.
“We appointed David in 2009 because his pedigree as a senior executive as well as his packaging business expertise was clear,” said Chief Executive of the Clondalkin Group, Norbett McDermott. “He has continued to prove himself to be an invaluable leader in consolidating our position as a leading producer of secondary pharmaceutical packaging.”
Rick Stewart has been appointed to The Board of Directors at BioLife Solutions – a contract media manufacturer.
Since 2001, Stewart has been President and CEO of Cardiac Dimensions and prior to this role he was CEO at Tegris Corporation and has also worked for Eli Lilly.
BioLife Chairman and CEO expressed his pleasure in the appointment of Stewart adding: “We are generating record revenues and on a significant growth path, and Rick's extensive life sciences and operations background will make his counsel and participation invaluable as we seek to generate more shareholder value.”
Stewart replaces Howard Breslow who recently resigned from the board.
Oncology services company Biologics has appointed Ron Smith as Chief Operating Officer to Executive Team.
Smith comes from Physicians Pharma Alliance where he also served as Chief Operating Officer.
Stuart Frantz, President & CEO at Biologics said: “We are experiencing exceptional growth and Ron’s intelligence, leadership skills and clinical background will assist Biologics in navigating our expansion.”
Talking of growth, biologics has also promoted Daniel S. Duffy to Chief Business Development Officer having previously been Executive Vice-President and General Manager.
“His experience coupled with his passion for delivering exceptional service to our partners and patients has helped lay the foundation for continued growth throughout the company,” said Frantz expressing his pleasure of the appointment.